Dehydroepiandosterone, Intravaginal

Drug Overview

Menopause brings a variety of changes to a woman’s body, and while hot flashes often get the most attention, localized changes in the pelvic region can be equally disruptive to daily life and intimacy. Within the Gynecology drug category, advanced treatments have been developed to address these deeply personal concerns safely and effectively. Intravaginal dehydroepiandrosterone (DHEA) is a groundbreaking prescription medication belonging to the Steroid Hormone (DHEA) drug class.

Operating as a highly specialized Hormone Modulator, intravaginal DHEA offers a completely unique approach to treating menopausal vaginal changes. Unlike traditional hormone therapies that introduce active estrogens into the body, this medication provides an inactive precursor. Your body’s own cells convert it locally into the exact amounts of hormones they need, restoring the natural health of vaginal tissues without significantly raising hormone levels in your bloodstream.

• Generic Name: Prasterone (synthetic dehydroepiandrosterone or DHEA)
• US Brand Names: Intrarosa
• Route of Administration: Intravaginal (administered as a small, daily insert or suppository)
• FDA Approval Status: Fully FDA-approved for the treatment of moderate to severe dyspareunia (painful sexual intercourse), a common symptom of vulvar and vaginal atrophy (VVA) due to menopause.

What Is It and How Does It Work? (Mechanism of Action)

To understand how this medication provides relief, we must first look at what happens to the female reproductive system during menopause. During your reproductive years, the ovaries produce high levels of estrogen and testosterone, which keep the vaginal tissues thick, elastic, and well-lubricated. When menopause occurs, ovarian hormone production dramatically drops. Deprived of these hormones, the vaginal walls become thin, fragile, dry, and easily inflamed—a condition known as vulvar and vaginal atrophy (VVA).

Intravaginal DHEA acts as a highly precise Targeted Therapy to reverse this process through a fascinating biological mechanism known as “intracrinology.”

The active ingredient, prasterone, is not an active hormone itself; it is a precursor molecule. When the small insert melts inside the vagina, the prasterone is absorbed directly into the cells of the vaginal wall. Inside these specific cells, local enzymes convert the DHEA into active intracellular estrogens and androgens (like testosterone).

At the molecular level, these newly created hormones bind to estrogen and androgen receptors inside the nucleus of the vaginal cells. This receptor activation signals the cells’ DNA to start dividing and multiplying again. The estrogenic action rebuilds the thickness of the vaginal wall and restores healthy glycogen production, which brings back the natural, protective acidic pH of the vagina. Simultaneously, the androgenic (testosterone) action helps regenerate local nerve endings and improves the muscle tone and elasticity of the vaginal tissues.

Because all of this hormone conversion and receptor activation happens entirely inside the vaginal cells, the hormones are inactivated before they leak back into the main bloodstream. Therefore, this Hormone Modulator treats the local tissue atrophy directly without disrupting the rest of the body or stimulating the uterine lining.

FDA-Approved Clinical Indications

This medication is utilized strictly within the scope of gynecological health to manage the localized physical symptoms of hormone deficiency.

Primary Gynecological/Obstetric Indications

• Dyspareunia (Painful Intercourse): The primary, FDA-approved indication is the treatment of moderate to severe pain during sexual intercourse, which is a hallmark symptom of menopausal vulvar and vaginal atrophy (VVA).
• Genitourinary Syndrome of Menopause (GSM): Serves as a foundational treatment for the broader category of GSM, actively reversing the underlying tissue thinning that causes vaginal burning, itching, and dryness.

Off-Label / Endocrinological Indications

• Vaginal Dryness (Without Painful Sex): Frequently prescribed off-label for postmenopausal women whose primary complaint is severe daily vaginal dryness and irritation, even if they are not sexually active.
• Mild Stress Urinary Incontinence: Used off-label to strengthen the pelvic tissues supporting the urethra, which can reduce mild urinary leakage associated with menopause.
• Lichen Sclerosus Adjunct: Occasionally utilized off-label as a supportive therapy alongside topical steroids to improve the elasticity of vulvar tissues affected by this chronic skin condition.

Dosage and Administration Protocols

Intravaginal DHEA is designed for ease of use and consistent daily relief. It comes as a solid, bullet-shaped waxy insert that is placed directly into the vagina.

Dose Adjustments and Special Populations:

• Hepatic and Renal Insufficiency: Because intravaginal DHEA is converted and metabolized locally within the vaginal tissues and does not significantly enter systemic circulation, no specific dose adjustments are required for patients with mild to moderate kidney or liver impairment.
• History of Breast Cancer: While this medication does not raise systemic estrogen levels above normal postmenopausal ranges, it has not been extensively studied in women with a history of breast cancer. It should only be used in this population after a careful consultation with the patient’s oncologist.

Clinical Efficacy and Research Results

Current clinical literature from 2020 to 2026 continues to heavily validate the profound efficacy of intravaginal DHEA for restoring vaginal health.

Efficacy is routinely measured using standard gynecological parameters: the Vaginal Maturation Index (VMI), vaginal pH levels, and patient-reported pain scores. Robust clinical trials demonstrate that daily administration of the 6.5 mg prasterone insert completely alters the vaginal cellular profile within 12 weeks. Researchers consistently note a drastic 40 to 50 percent decrease in fragile, immature parabasal cells, accompanied by a significant 10 to 15 percent increase in healthy, robust superficial cells. Concurrently, the vaginal pH drops from an infection-prone, alkaline state (often above 5.5) to a healthy, acidic baseline (below 4.5).

From a patient symptom perspective, the results are highly encouraging. In clinical data utilizing the Visual Analog Scale (VAS) for dyspareunia, women utilizing this Targeted Therapy report an average pain reduction of over 1.5 points on a 3-point severity scale after 12 weeks of use. Over 80 percent of patients report that sexual intercourse transitions from painful to comfortable and pleasurable within three to six months of continuous daily use.

Safety Profile and Side Effects

Unlike traditional vaginal estrogen products with FDA “Black Box Warnings” for cardiovascular and endometrial risks, intravaginal DHEA (Intrarosa) has no boxed warning, reflecting its localized safety.

Common Side Effects (>10%)

• Vaginal Discharge: Increased discharge from the waxy base melting—normal and self-resolving.
• Abnormal Pap Smear: Rare, temporary atypical cervical cells during tissue regeneration.

Serious Adverse Events & Management

• Undiagnosed Vaginal Bleeding: Contraindicated in women with unexplained bleeding; rule out uterine cancer first.
• Hormone-Sensitive Cancers: Minimal systemic absorption, but caution advised.

Management Tips:

• Apply before sleep and use a breathable cotton liner to manage discharge.
• Stop medication and contact a gynecologist immediately if unexpected spotting occurs; a pelvic ultrasound may be required.

Connection to Stem Cell and Regenerative Medicine

Recent gynecological research (2023–2026) highlights the role of intravaginal DHEA as a preparatory “tissue priming” step in regenerative medicine. Daily use for 4–8 weeks thickens, hydrates, and vascularizes vaginal walls before Autologous PRP injections or Fractional CO₂ Laser therapy. By improving local blood flow and cellular readiness without systemic estrogen exposure, this targeted therapy enhances healing, success rates, and long-term outcomes of advanced regenerative procedures.

Patient Management and Practical Recommendations

Effective patient management ensures that the life-changing benefits of this localized therapy are maximized while keeping the patient comfortable and well-informed.

Pre-Treatment Tests

• Pelvic Exam and Pap Smear: A comprehensive clinical gynecological exam is necessary to confirm the diagnosis of atrophy and rule out other underlying pelvic conditions.
• Mammogram: Routine, age-appropriate breast cancer screenings should be up to date before initiating any hormone-related therapy.
• Medical History: A thorough review to ensure the patient has no history of unexplained postmenopausal vaginal bleeding.

Precautions During Treatment

• Barrier Contraception Weakening: The waxy, fat-based ingredients used to formulate the DHEA insert can weaken and break down latex or rubber products. Polyurethane condoms or alternative non-latex barriers should be used, as traditional latex condoms and vaginal diaphragms may fail if used alongside this medication.
• Partner Exposure: Because the medication converts to active hormones entirely inside your cells, there is virtually no risk of transferring active hormones to your sexual partner, making it highly safe for intimate contact.

“Do’s and Don’ts” list

• DO insert the medication strictly at bedtime while lying down to ensure the melted medication stays in the vaginal canal and fully coats the tissues.
• DO use the disposable applicators provided in the package, and discard each applicator after a single use to maintain strict pelvic hygiene.
• DO wear a cotton panty liner overnight to protect your undergarments from the harmless waxy discharge.
• DON’T use the insert if you are experiencing active, undiagnosed vaginal bleeding.
• DON’T stop using the medication simply because your symptoms improve. Vaginal atrophy is a chronic condition; if you stop the medication, the pain and dryness will eventually return.
• DON’T worry about severe systemic side effects like weight gain or mood swings, as this targeted therapy stays safely within the vaginal tissues.

Legal Disclaimer

The medical information provided in this comprehensive guide is intended solely for educational and informational purposes and does not constitute professional medical advice, diagnosis, or treatment. Every patient’s medical history is unique. Always seek the direct advice of your physician, gynecologist, or other qualified healthcare provider regarding any questions you may have about a medical condition, menopausal symptoms, or before starting, stopping, or altering any prescribed medication regimen.